The nation of Zimbabwe has rejected a substantial US healthcare agreement worth 367 million US dollars (£272m) spanning five years over the United States' request for sensitive data.
The decision came to light following a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
A government spokesman has since stated that the US was requesting biological samples for research and profit while refused to share the benefits from future treatments.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for continued dialogue to secure a agreement suitable to all parties so the nation's critical HIV programme can be sustained.
Wider Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a high court halted a similar deal with the US after concerns were filed about the safety of Kenyans' medical information.
After resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to boost openness and accountability.
According to statements, Sixteen nations in Africa have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no equivalent assurance of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," he stated.
"Put simply, our country would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our citizens if a future health crisis arise."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining frameworks already set up through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This system is designed to ensure that when a nation contributes its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing dialogue with our US partners on how future collaboration might be designed in a manner that honours the sovereignty and interests of each country."
Medical Community Response
A leading public health body expressed it understood the official position, but suggested that talks must proceed given that a large portion of the nation's HIV programmes were funded by international support.
"Where specific concerns arise, such as those relating to data governance or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," the group said.
The halted deal underscores the complex debate between accepting vital foreign assistance and safeguarding local interests in an ever more data-driven world.